



PATENT

Case Docket No. DECLE55.1CP2DV

Date: September 16, 2002

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Moser et al.  
App. No. : 09/802,397  
Filed : March 9, 2001  
For : DENDRITIC-LIKE  
CELL/TUMOR CELL  
HYBRIDS AND  
HYBRIDOMAS FOR  
INDUCING AN ANTI-  
TUMOR RESPONSE

Group Art Unit : 1636

I hereby certify that this correspondence and all marked  
attachments are being deposited with the United States  
Postal Service as first class mail in an envelope addressed  
to: United States Patent and Trademark Office, P.O. Box  
2327, Arlington, VA 22202, on

September 16, 2002

(Date)

Catherine M. Sanders, Reg. No. 50,660

RECEIVED

SEP 25 2002

TECH CENTER 1600/2900

## TRANSMITTAL LETTER

United States Patent and Trademark Office  
P.O. Box 2327  
Arlington, VA 22202

Dear Sir:

In response to the Notice to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures which was mailed by the Office on June 17, 2002, enclosed are:

- (X) An Amendment and Sequence Submission Statement.
- (X) A paper copy of the Sequence Listing.
- (X) A computer readable Sequence Listing disk.
- (X) An extension of time to respond for two months is hereby requested.

Time Extension Fee:

- ( ) one month (\$110 large entity)
- (X) two months (\$400 large entity)
- ( ) three months (\$920 large entity)

09/23/2002 SHINASS1 00000066 09802397 400.00 OP  
01 FC:116


**PATENT**

Case Docket No. DECLE55.1CP2DV

Date: September 16, 2002

---

- (X) Return prepaid postcard.
- (X) A check in the amount of \$400.00 to cover the above fees is enclosed.
- (X) The Commissioner is hereby authorized to charge any additional fees which may be required, now or in the future, or credit any overpayment, to Account No. 11-1410.



Catherine M. Sanders

Registration No. 50,660

Agent of Record



Application No.: 09/802,397

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING  
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other: \_\_\_\_\_

**RECEIVED**

SEP 25 2002

**Applicant Must Provide:**

**TECH CENTER 1600/2900**

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY**